Creo Medical Achieves Key U.S. Reimbursement Milestone for ESD Procedures

An update from Creo Medical ( (GB:CREO) ) is now available.

Creo Medical Group plc has announced a significant milestone with the American Medical Association’s approval of two new Category I CPT reimbursement codes for Endoscopic Submucosal Dissection (ESD) procedures in the U.S. This development is expected to enhance access to advanced, minimally invasive surgical options for patients with early-stage cancerous and pre-cancerous lesions in the gastrointestinal tract. The new reimbursement framework is anticipated to drive broader adoption of ESD procedures, benefiting approximately 5% of the U.S. population over 50 who could potentially benefit from such treatments. Additionally, this milestone is set to encourage the use of Creo’s next-generation products, such as Speedboat® UltraSlim, furthering medical innovation and improving patient outcomes.

More about Creo Medical

Creo Medical Group plc is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. The company focuses on enhancing endoscopic procedures through advanced energy technologies, aiming to improve patient outcomes with its suite of electrosurgical medical devices powered by CROMA and Kamaptive technology. This technology provides clinicians with increased flexibility, precision, and control during surgical procedures, offering a safer, less invasive, and more cost-efficient option for surgeries and endoscopies.

Average Trading Volume: 1,579,809

Technical Sentiment Signal: Sell

Current Market Cap: £51.56M

For detailed information about CREO stock, go to TipRanks’ Stock Analysis page.